151 related articles for article (PubMed ID: 35932399)
1. Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
Tsuda M; Hirata A; Tokunaga S; Masuda T; Haji S; Kimura D; Nojiri C; Nakashima Y; Shiratsuchi M; Kato K; Miyamoto T; Akashi K; Nakashima N; Ogawa Y
Int J Hematol; 2022 Dec; 116(6):863-870. PubMed ID: 35932399
[TBL] [Abstract][Full Text] [Related]
2. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.
Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
[TBL] [Abstract][Full Text] [Related]
3. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
[TBL] [Abstract][Full Text] [Related]
4. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.
Hino A; Yoshida H; Tada Y; Koike M; Minami R; Masaie H; Ishikawa J
Int J Hematol; 2016 Nov; 104(5):605-611. PubMed ID: 27460678
[TBL] [Abstract][Full Text] [Related]
5. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
6. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
8. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
Okamoto S; Ureshino H; Kawaguchi A; Miyazono M; Ikeda Y; Kimura S
Int J Hematol; 2020 Jul; 112(1):41-45. PubMed ID: 32306183
[TBL] [Abstract][Full Text] [Related]
9. Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients.
Singh AK; Hussain S; Ahmed R; Agrawal N; Bhurani D; Klugar M; Sharma M
Nephrology (Carlton); 2022 Apr; 27(4):318-326. PubMed ID: 34894374
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
13. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
Ren X; Qin Y; Huang X; Zuo L; Jiang Q
Ann Hematol; 2019 Jul; 98(7):1627-1640. PubMed ID: 31089794
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
15. [Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Matmour D; Si-Ali N; Benmehimda NC; Beloufa S; Belfrak F; Mahi E; Merad Y; Toumi H; Benlazar M
Ann Pharm Fr; 2022 Nov; 80(6):932-942. PubMed ID: 35469781
[TBL] [Abstract][Full Text] [Related]
16. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ
Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564
[TBL] [Abstract][Full Text] [Related]
17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
[TBL] [Abstract][Full Text] [Related]
19. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
